Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Tuesday

Key Points

• Supernus will report Q1 2026 results after the close on Tuesday, May 5, 2026; analysts expect $0.26 EPS and $192.96 million in revenue, and a conference call is scheduled for 4:30 PM ET.
• Analyst coverage is mixed — four Buys, one Hold and two Sells — producing an average rating of Hold and a mean target price of $62.17, with notable downgrades from Zacks and Wall Street Zen and a $65 target from Craig Hallum.
• Insiders sold 120,881 shares (~$6.14 million) in the last quarter, and the stock trades near $49.46 with a market cap of $2.85 billion and a negative P/E of -72.73.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.26 per share and revenue of $192.9570 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $49.46 on Tuesday. The business has a 50 day simple moving average of $51.30 and a 200 day simple moving average of $49.91. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $59.68. The stock has a market capitalization of $2.85 billion, a P/E ratio of -72.73, a P/E/G ratio of 1.55 and a beta of 0.73.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research cut Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. Wall Street Zen cut Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Sunday, March 8th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Hold" and an average target price of $62.17.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total value of $537,100.00. Following the transaction, the director owned 28,159 shares in the company, valued at approximately $1,512,419.89. This represents a 26.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frederick M. Hudson sold 5,369 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the transaction, the director owned 60,413 shares in the company, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 120,881 shares of company stock valued at $6,139,356. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning bought a new position in Supernus Pharmaceuticals in the second quarter worth approximately $242,000. Fieldview Capital Management LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $242,000. Corient Private Wealth LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $237,000. Atom Investors LP purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $224,000. Finally, Mackenzie Financial Corp purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $223,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.